Williams Jones Wealth Management’s Spero Therapeutics SPRO Stock Holding History

Williams Jones Wealth Management’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-19,000	Closed	-$38K	–	584
2022 Q3	$38K	Hold	19,000	–	–	﹤0.01%	554
2022 Q2	$14K	Sell	19,000 -7,000	-27%	-$20.4K	﹤0.01%	564
2022 Q1	$226K	Sell	26,000 -49,000	-65%	-$502K	﹤0.01%	465
2021 Q4	$1.2M	Sell	75,000 -30,500	-29%	-$484K	0.02%	245
2021 Q3	$1.94M	Buy	+105,500	New	+$1.69M	0.03%	196

Other funds holding SPRO

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Williams Jones Wealth Management's SPRO Position: Q4 2022 in Review

Williams Jones Wealth Management sold out of Spero Therapeutics (SPRO) in Q4 2022, closing a stake of 19,000 shares — an estimated $38K sold.

Williams Jones Wealth Management first reported a position in SPRO in Q3 2021 and held it in 5 quarters. The position peaked at $1.94M in Q3 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

Williams Jones Wealth Management reported no remaining Spero Therapeutics position as of Q4 2022 after selling out during the quarter.
Williams Jones Wealth Management sold 19,000 Spero Therapeutics shares in Q4 2022, an estimated $38K.
Williams Jones Wealth Management first reported a position in Spero Therapeutics in Q3 2021 and held it in 5 quarters.
Williams Jones Wealth Management's Spero Therapeutics position peaked at $1.94M in Q3 2021.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on Williams Jones Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2023.